U.S. markets open in 6 hours 56 minutes

AbbVie Inc. (ABBV)

NYSE - NYSE Delayed Price. Currency in USD
Add to watchlist
105.90-1.02 (-0.95%)
At close: 4:02PM EDT
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bearishpattern detected
Double Moving Average Crossover

Double Moving Average Crossover

Previous Close106.92
Open106.22
Bid0.00 x 900
Ask0.00 x 4000
Day's Range105.58 - 106.67
52 Week Range79.11 - 113.41
Volume6,782,316
Avg. Volume7,378,685
Market Cap186.895B
Beta (5Y Monthly)0.81
PE Ratio (TTM)38.93
EPS (TTM)2.72
Earnings DateApr 30, 2021
Forward Dividend & Yield5.20 (4.81%)
Ex-Dividend DateApr 14, 2021
1y Target Est122.17
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued
-44% Est. Return
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
View more
  • Got $1,000? 2 Dirt-Cheap Value Stocks You Can Buy Right Now
    Motley Fool

    Got $1,000? 2 Dirt-Cheap Value Stocks You Can Buy Right Now

    For instance, the S&P 500's cyclically adjusted price-to-earnings ratio -- a measure of the stock market's valuation -- is currently 36.6, the highest it has been in more than 10 years. Right now, two such companies are AbbVie (NYSE: ABBV) and Pfizer (NYSE: PFE). AbbVie currently trades for just 8.7 times forward earnings, while its price-to-earnings growth ratio (PEG) is 0.19.

  • Motley Fool

    Should AbbVie Be Worried About Rinvoq?

    The U.S. Food and Drug Administration (FDA) has now pushed back two reviews for regulatory filings by AbbVie (NYSE: ABBV) for Rinvoq. This autoimmune disease drug is an important component of the company's growth strategy. In this Motley Fool Live video, recorded on April 7, 2021, Motley Fool contributors Keith Speights and Brian Orelli discuss whether or not AbbVie and its shareholders should be worried about Rinvoq.

  • Top Research Reports for Home Depot, Toyota & IBM
    Zacks

    Top Research Reports for Home Depot, Toyota & IBM

    Top Research Reports for Home Depot, Toyota & IBM